← Home

EMV

Healthcare & BiotechNEUTRAL

$1.600

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted
WAWealth & advisers+$125k
NIBInvestment banks+$95k
RetailRetail · context+$63k
MMMarket makers−$198
ResResource specialists−$16k

5d return

-4.5%

20d return

+6.3%

60d return

-14.9%

RSI 14

53.5

vs 52w high

-32.5%

vs 52w low

+8.1%

SMA 20

Above

SMA 50

Below

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Closest correlates
Pearson r on log returns, window: 42d
  • ASNr=0.47, window: 42d
  • DTIr=0.47, window: 42d
  • CXOr=0.44, window: 42d
  • VMMr=0.44, window: 42d
  • WC8r=0.42, window: 42d
Announcements — last 30 days
  • 2026-07-15PSotherQuarterly Activities/Appendix 4C Cash Flow Report

    EMVision has passed pivotal stroke-detection trial recruitment milestones with no device-related adverse events, and is preparing to expand the emu™ validation to include acute ischaemia detection via FDA pre-submission—a material clinical and commercial expansion from launch. Strong non-dilutive funding position ($17.1m cash + $4.6m remaining grants) supports runway through anticipated FDA De Novo submission in CY26/early CY27.

  • 2026-07-14emu AI methods & insights published in npj Digital Medicine